Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenon Medical, Inc. filings document its medical-device business, public securities, and material events tied to sacroiliac joint treatment products. Current Reports on Form 8-K cover financial results, unaudited revenue releases, FDA-cleared product updates, and corporate communications related to the Catamaran System and SImmetry® portfolio.
The filing record also discloses securities purchase agreements, senior convertible notes, private placements of common stock and warrants, restricted stock unit grants under the 2022 Equity Incentive Plan, annual meeting voting matters, Nasdaq listing-compliance notices, and amended acquisition disclosures with financial statements and pro forma information for the SiVantage asset acquisition.
Tenon Medical, Inc. entered into securities purchase agreements for $4.3 million aggregate principal amount of 20% original issue discount senior convertible promissory notes in a private placement with accredited investors. The notes mature on September 11, 2026, with an option to extend to December 11, 2026, which increases the outstanding principal by 5%. After six months, they are convertible into common stock at a price equal to 80% of the volume-weighted average price over the three trading days before conversion, subject to adjustment. Any prepayment is at 102.5% of principal, and 15% of net proceeds from future securities financings must be used to prepay the notes. WallachBeth Capital LLC acted as placement agent, earning a 7% cash fee on gross proceeds plus $65,000 in expenses. Tenon expects to use net proceeds for commercial expansion, product development, clinical studies, working capital and general corporate purposes. The offering relied on exemptions from registration under Section 4(a)(2) and Regulation D/Rule 506(b).
Tenon Medical, Inc. Chief Financial Officer Kevin Williamson acquired shares through equity award activity. On March 3, 2026, 1,041 restricted stock units granted on November 5, 2024 converted into 1,041 shares of common stock. After these transactions, he directly held 43,593 common shares and 3,126 restricted stock units.
Tenon Medical, Inc. has been notified by Nasdaq that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days between January 9 and February 24, 2026, triggering a deficiency under Nasdaq’s bid price rule.
The company has 180 calendar days, until August 24, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. If it still fails, Tenon may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially through a reverse stock split.
Tenon’s shares continue to trade on The Nasdaq Capital Market under the symbol “TNON” while the company evaluates its options. However, failure to regain or maintain compliance could ultimately lead to delisting, though the company would have the right to appeal any delisting determination.
Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.
For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.
Tenon Medical, Inc. director reports RSU vesting and share sale
A director of Tenon Medical, Inc. (TNON) reported equity transactions involving restricted stock units and common stock. On January 1, 2026, 10,732 restricted stock units converted into 10,732 shares of common stock, increasing the director’s holdings. On January 5, 2026, 3,327 shares of common stock were disposed of at a price of $0.9301 per share to satisfy tax liabilities related to the RSU vesting. Following these transactions, the director directly held 8,462 shares of common stock.
Tenon Medical, Inc. (TNON) CEO and President Steven Foster reported buying additional company stock in a private transaction. On November 14, 2025, he purchased 19,455 shares of common stock, increasing his direct holdings to 22,878 shares after the transaction. The purchase was part of a securities purchase agreement for a private investment in which each share of common stock was sold together with a warrant.
Along with the shares, Foster also acquired warrants to purchase up to 19,455 additional common shares. The combined purchase price for each share and accompanying warrant was $1.285, and the warrants have an exercise price of $1.16 per share and expire on November 14, 2028. These details show how a key executive has recently committed more capital to Tenon Medical through both stock and long-term warrants.
Tenon Medical's Chief Innovation Officer reported buying additional stock and warrants in the company. On November 14, 2025, the officer purchased 19,455 shares of common stock in an at-the-market private investment in public equity transaction at a combined price of $1.285 per share and accompanying warrant.
The officer also received warrants to purchase up to 19,455 shares of common stock at an exercise price of $1.16 per share, exercisable starting November 14, 2025 and expiring November 14, 2028. Following this transaction, the officer directly beneficially owned 157,569 shares and indirectly beneficially owned 350,765 shares through SiVantage, Inc.
Tenon Medical, Inc. (TNON) reported that its Chief Commercial Officer filed a Form 4 disclosing participation in an at-the-market private investment in public equity transaction. On November 14, 2025, the officer purchased 101,167 shares of common stock and received warrants to purchase up to 101,167 additional shares of common stock. The purchase price for each share and accompanying warrant unit was $1.285.
The warrants have an exercise price of $1.16 per share and are exercisable from November 14, 2025 until November 14, 2028. Following the transaction, the officer directly beneficially owned 239,281 shares of common stock and indirectly held 175,383 shares through SiVantage, Inc., reflecting a 24.69% equity interest in that entity.
Tenon Medical, Inc. entered into securities purchase agreements with accredited investors to sell 2,217,904 shares of common stock and accompanying warrants at a combined price of $1.285 per share and warrant. The warrants have an exercise price of $1.16 per share and a three-year term. The offering closed with the issuance of 2,217,904 shares and warrants to purchase 2,217,904 shares, providing approximately $2.85 million in gross proceeds that the company plans to use for working capital and general corporate purposes. Senior executives, including the CEO, CCO, and Chief Innovation Officer, participated as purchasers. The company must file a registration statement for the shares and warrant shares within 30 days, and the transaction was conducted as an unregistered private placement under Section 4(a)(2) and Regulation D.
Tenon Medical (TNON) reported Q3 results and completed two asset acquisitions to expand its SI joint portfolio. Revenue was $1.173 million versus $0.887 million a year ago, with gross margin improving to 66% from 47% as higher volumes reduced fixed production costs per unit. Net loss was $3.339 million compared with $3.184 million.
Cash and cash equivalents were $3.442 million as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern for one year after issuance, and plans to seek additional financing.
In August, Tenon acquired substantially all assets of SiVantage and SIMPL (treated as a single business combination) for total consideration of $3.127 million, including $0.75 million in cash, 710,300 shares, and contingent consideration; goodwill recorded was $2.407 million. As a subsequent event, the company announced a $2.85 million PIPE financing, issuing 2,217,904 common shares and warrants to purchase 2,217,904 shares at a combined price of $1.285 per share-and-warrant, with warrants exercisable at $1.16.
Shares outstanding were 8,605,740 as of November 13, 2025.